We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Biopharmas

News List

Biopharmas to disclose payments to nurses under bipartisan opioid bill fiercepharma
September 28, 2018
Drug and medical device manufacturers have been reporting financial relationships with physicians to the U.S. government for years under the Physician Payments Sunshine Act.
Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg fiercepharma
June 29, 2018
Biopharma M&A has picked up this year with deals dominated by rare diseases and cancer, more than $34 billion all told, not counting Takeda's hefty $62 billion offer for Shire.
Where do big-cap biopharmas stand on the M&A matrix? fiercepharma
May 30, 2018
Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst
6 Promising Biopharmas With Major Catalysts in 2018 biospace
January 30, 2018
Not only is the biopharma market expected to be a hot one for mergers and acquisitions this year, but it’s expected to be hot for stocks as well.
4 Major Biopharmas: What Went Down at JPM 2018 biospace
January 12, 2018
The J.P. Morgan Healthcare Conference is a yearly opportunity for the biopharma industry to make major announcements and let analysts, investors and the media pick the brains of top execs